Founded in 2005 through the merger of two Japanese pharmaceutical companies, Astellas has quickly established itself as a major player in the global pharmaceutical industry, with a focus on fields such as urology, immunology, and infectious diseases. The company is committed to investing in research and development to create new treatments for a range of medical conditions, and is also expanding its global presence through partnerships and acquisitions. Despite facing challenges such as patent expirations and regulatory scrutiny, Astellas is poised for continued growth in the years ahead as it continues to bring innovative treatments to patients in need.